Brief: Hyphens Pharma International Says Unit Gets Exclusive Rights To Commercialise Metoject
11/03/2025 14:32
March 11 (Reuters) - Hyphens Pharma International Ltd HYPH.SI: UNIT GETS EXCLUSIVE RIGHTS TO COMMERCIALISE METOJECT IN SINGAPORE, MALAYSIA, PHILIPPINES, VIETNAM Further company coverage: HYPH.SI ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Hyphens Pharma International
See all newsBrief: Hyphens Pharma International Updates On Cerapro® Med Skin Barrier Cream
Brief: Hyphens Pharma International Says Unit Gets Exclusive Rights To Commercialise Metoject
Brief: Hyphens Pharma International Posts FY Net Income Of SGD 10.9 Million
Brief: Hyphens Pharma International Licenses Amenalief From Maruho For ASEAN
Brief: Hyphens Pharma International Posts Net Profit After Tax In 1Q2024 S$2.7 Million